Asalyxa Bio Closes Seed Financing to Advance Lead Program into First-in-Human Clinical Studies
24 Feb, 2021
– HemoShear Therapeutics, Inc. is a clinical stage company developing treatments for rare metabolic disorders.
– The company raised $40m in Series A funding.
– The round was led by Suvretta Capital with participation from Janus Henderson Investors, Adage Capital Management LP and other private investors.
– The new investment will be used to complete a phase 2 study of its lead compound, HST5040, an investigational oral small molecule therapy, for the treatment of methylmalonic acidemia (MMA) and propionic acidemia (PA), as well as fund future clinical studies and earlier stage programs.